Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.73 |
| ▸ | DRD1 | P21728 | 1/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | PDE4A | P27815 | 1/20 | 0.73 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.36 |
| ▸ | NECTIN4 | Q96NY8 | 11/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.35 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.35 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.35 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15507436 | 0.98 | CTSL (0.76) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL13246868 | 0.94 | CTSL (0.83) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL15177343 | 0.94 | CTSL (0.83) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL13267826 | 0.94 | CTSL (0.76) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL13267792 | 0.92 | CTSL (0.73) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL13267659 | 0.91 | CTSL (0.79) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL15507446 | 0.90 | CTSL (0.76) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL8418337 | 0.88 | CTSL (0.84) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL8420337 | 0.88 | CTSL (0.84) | CTSLDRD1PTGS1PDE4AEPHA2 | |
| SCHEMBL13246855 | 0.87 | CTSL (0.86) | CTSLDRD1PTGS1PDE4AEPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | CTSL 56/4885DRD1 2791/4885PTGS1 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.